In the June issue of Contract Pharma, IQVIA Laboratories' Chief Scientific Officer Patrice Hugo discusses the breadth of new tech-enabled analytical laboratory techniques that are making an impact in end-to-end complex drug development. This includes everything from advanced flow cytometry to high-resolution mass spectrometry and in-depth RNA/DNA sequencing.
In this feature article, Dr. Hugo provides the "why" behind the excitement among lab specialists for transformative analytical advances. He also emphasizes the importance of what underpins the use of these solutions to effectively meet the demands of today's clinical trials, including deep expertise, operational consistencies among lab sites for data comparability, therapeutic considerations and more.
Click here to read the full article.
Related Insights
Managing Informed Consent Samples from Clinical Trials
A set of best practices for the definition, tracking and management of allowable use attributes associated with samples collected in protocol based clinical trials
Biorepository and Specimen Management
Your biological specimens are irreplaceable assets – trust them with a proven partner
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
IQVIA Laboratories Central Laboratory Services
Central laboratory solutions supporting clinical trials around the world
Helping you master your lab data
Improved oversight with your lab data now in full view
NASH and Liver Disease Capabilities
Nonalcoholic Fatty Liver Diseases & Non-alcoholic Steatohepatitis (NAFLD & NASH)
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Pediatric Initiative
Optimizing small blood volumes to prevent canceled tests in clinical trials for pediatric patients
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
